Heparin-Induced Thrombocytopenia Clinical Trial
Official title:
Heparin Antibodies in Intensive Care Unit Patients (HAICU)
Intensive care unit patients have multiple risk factors for venous thromboembolism. Venous
thromboembolism leads to significant morbidity and can be fatal. Unfractionated heparin and
low molecular weight heparin are commonly used to prevent venous thromboembolism. Heparin
induced thrombocytopenia, an untoward consequence of exposure to heparin, is an immune
disorder that may develop in patients treated with heparin products. Determining the
prevalence of heparin induced thrombocytopenia and its relationship to preventive and
therapeutic heparin and low molecular weight heparin will help clinicians more appropriately
choose methods of venous thromboembolism prophylaxis and treatment in the critically ill,
ICU population.
The objective of this study is to determine the prevalence of heparin-induced antibodies on
admission to the ICU and the development of new heparin-antibodies during the first week of
hospitalization.
Venous Thromboembolism (VTE) is common in the intensive care unit (ICU); VTE leads to
significant morbidity and is fatal in 30% of undiagnosed pulmonary emboli and 8% when PE is
appropriately treated. Intensive care unit (ICU) patients have multiple risk factors for VTE
and tend to be at higher risk than non-ICU patients. Risk factors specific to ICU patients
include immobility, central venous catheters, sepsis or infection, need for vasopressors,
mechanical ventilation, surgery, trauma, and increasing age. Guidelines exist for the
prevention of VTE, and VTE prophylaxis is strongly recommended. Given the high rate of VTE
and the attendant morbidity and mortality, most ICU's routinely provide VTE prophylaxis
which is individualized according to risk-benefit analysis with respect to thrombosis and
bleeding risk. Prophylaxis for patients at risk of bleeding is accomplished by using
mechanical compression devices while those without bleeding risk are administered medical
prophylaxis which is felt to be more effective.
Recently, it has become apparent that medical prophylaxis is not without risk and that the
risk-benefit analysis should also include the risk of developing heparin induced
thrombocytopenia (HIT) or heparin induced thrombocytopenia with thrombosis (HITT).
Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are commonly used to
prevent VTE in ICU and non-ICU patients. HIT, an untoward consequence of exposure to heparin
is an immune disorder that may develop in patients treated with heparin products. HIT is
antibody mediated, usually due to IgG antibodies directed against epitopes on the platelet
surface comprised of the heparin-platelet factor 4 complex. HIT is generally characterized
by a decrease in platelet count to less than 100 X 109/L, or a 50% decrease from baseline,
after exposure to heparin. HIT is typically observed after 5 to 10 days of treatment.
Alternatively, patients with previous exposure to heparin can develop HIT in two days while
heparin naive patients may develop HIT in about 10 days. The platelet count usually returns
to normal several days after discontinuing heparin with or without therapy, though the risk
for thrombosis persists for up to 3 months due to the persistence of antibodies.
Using an ELISA assay heparin-induced antibody formation is found in up to 50% of patients
exposed to UFH. However, the serotonin release assay (SRA) which is believed to be more
specific for HIT detects antibody formation in about 20% of patients. Five percent of
patients receiving UFH develop thrombocytopenia (HIT) and half of these patients go on to
develop heparin induced thrombocytopenia with thrombosis (HITT) which results in venous and
arterial complications which can be life threatening, or result in loss of extremities.
The occurrence of HIT varies widely between clinical populations and is dependent on the
type of heparin used, i.e. UFH vs. LMWH. The highest incidence reported to date has been in
the cardiac and orthopedic populations and is unknown in the ICU population. Warkentin, et
al found in a study of 655 hip surgery patients that 2.7% randomized to UFH developed HIT
while none receiving enoxaparin (LMWH) developed HIT. This variability in development of
antibodies and the HIT syndrome makes it critically important to understand heparin induced
antibody formation as a precursor to HIT and HITT.
Determining the prevalence of HIT and its relationship to preventive and therapeutic UFH and
LMWH will help clinicians more appropriately choose methods of VTE prophylaxis and treatment
in the critically ill, ICU population.
Objectives To determine the prevalence of heparin-induced antibodies on admission to the ICU
and the development of new heparin-antibodies during the first 7 +/- 2 days of
hospitalization. Secondary objectives include: determining the incidence of heparin antibody
formation in patients treated with UFH, LMWH and mechanical prophylaxis (MPX); and to
compare the incidence of heparin antibodies between different ICU populations.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00759083 -
Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients
|
Phase 4 | |
Completed |
NCT00412464 -
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
|
Phase 1 | |
Completed |
NCT00456326 -
Heparin-Induced Thrombocytopenia Registry
|
N/A | |
Terminated |
NCT00673439 -
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
|
Phase 2 | |
Active, not recruiting |
NCT00198575 -
A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients
|
N/A | |
Not yet recruiting |
NCT05586854 -
Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia
|
N/A | |
Not yet recruiting |
NCT03269019 -
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
|
N/A | |
Not yet recruiting |
NCT06066762 -
Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
|
||
Terminated |
NCT03809481 -
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
|
Phase 3 | |
Completed |
NCT05325346 -
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
|
Phase 1 | |
Recruiting |
NCT02717039 -
Pharmacogenomics of Heparin-Induced Thrombocytopenia
|
||
Completed |
NCT02526485 -
Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
|
||
Completed |
NCT00748839 -
Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
|
N/A | |
Recruiting |
NCT05783895 -
Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery
|
||
Not yet recruiting |
NCT04782843 -
Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
|
||
Completed |
NCT00198588 -
Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia
|
Phase 3 | |
Recruiting |
NCT04842760 -
PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
|
||
Terminated |
NCT01598168 -
Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
|
Phase 3 | |
Completed |
NCT01654848 -
Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients
|
N/A | |
Withdrawn |
NCT00603824 -
Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)
|
Phase 4 |